Found: 277
Select item for more details and to access through your institution.
Use of Janus kinase inhibitors in atopic dermatitis – an update.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2024, v. 90, n. 3, p. 311, doi. 10.25259/IJDVL_14_2023
- By:
- Publication type:
- Article
Rapid progression of cutaneous T-cell lymphoma in a patient with erythroderma during dupilumab treatment, following prior sequential azathioprine, baricitinib and cyclosporine treatments.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2024, v. 90, n. 3, p. 353, doi. 10.25259/IJDVL_1090_2022
- By:
- Publication type:
- Article
Janus kinase inhibitors for alopecia areata: A narrative review.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2023, v. 89, n. 6, p. 799, doi. 10.25259/IJDVL_1093_2022
- By:
- Publication type:
- Article
Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study.
- Published in:
- Journal of Cosmetic Dermatology, 2024, v. 23, n. 4, p. 1417, doi. 10.1111/jocd.16123
- By:
- Publication type:
- Article
Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients With Coronavirus Disease 2019 (COVID-19) Using Nationwide Real-World Data: An Observational Matched Cohort Study From the Japan COVID-19 Task Force.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 7, p. 1, doi. 10.1093/ofid/ofad311
- By:
- Publication type:
- Article
P5‐47: Safety and efficacy of remdesivir, baricitinib and high‐dose steroid combination therapy in patients hospitalized with COVID‐19.
- Published in:
- Respirology, 2021, v. 26, p. 175, doi. 10.1111/resp.14150_254
- Publication type:
- Article
P5‐47: Safety and efficacy of remdesivir, baricitinib and high‐dose steroid combination therapy in patients hospitalized with COVID‐19.
- Published in:
- Respirology, 2021, v. 26, p. 175, doi. 10.1111/resp.14150_254
- Publication type:
- Article
Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-11879-1
- By:
- Publication type:
- Article
Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-10777-w
- By:
- Publication type:
- Article
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
- Published in:
- Journal of Personalized Medicine, 2024, v. 14, n. 7, p. 775, doi. 10.3390/jpm14070775
- By:
- Publication type:
- Article
Pharmacokinetics, Safety, and Tolerability of Single‐ and Multiple‐Dose Once‐Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo‐Controlled Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 8, p. 952, doi. 10.1002/cpdd.868
- By:
- Publication type:
- Article
Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.866441
- By:
- Publication type:
- Article
A Case Report of JAK Inhibitors Therapy for Adult-Onset Still's Disease with Persistent Pruritic Lesions.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still's Disease.
- Published in:
- Drugs in R&D, 2023, v. 23, n. 2, p. 109, doi. 10.1007/s40268-023-00417-7
- By:
- Publication type:
- Article
Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 12, p. 2714, doi. 10.3390/pharmaceutics14122714
- By:
- Publication type:
- Article
Baricitinib Liposomes as a New Approach for the Treatment of Sjögren's Syndrome.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 9, p. N.PAG, doi. 10.3390/pharmaceutics14091895
- By:
- Publication type:
- Article
Baricitinib Lipid-Based Nanosystems as a Topical Alternative for Atopic Dermatitis Treatment.
- Published in:
- Pharmaceuticals (14248247), 2023, v. 16, n. 6, p. 894, doi. 10.3390/ph16060894
- By:
- Publication type:
- Article
Impact of MnTBAP and Baricitinib Treatment on Hutchinson–Gilford Progeria Fibroblasts.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 8, p. 945, doi. 10.3390/ph15080945
- By:
- Publication type:
- Article
Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 10, p. 955, doi. 10.3390/ph14100955
- By:
- Publication type:
- Article
Current Status of Baricitinib as a Repurposed Therapy for COVID-19.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 7, p. 680, doi. 10.3390/ph14070680
- By:
- Publication type:
- Article
Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
- Published in:
- Inflammation, 2021, v. 44, n. 1, p. 206, doi. 10.1007/s10753-020-01322-w
- By:
- Publication type:
- Article
Design, synthesis, and biological evaluation of novel ruxolitinib and baricitinib analogues for potential use against COVID‐19.
- Published in:
- Chemical Biology & Drug Design, 2023, v. 101, n. 3, p. 760, doi. 10.1111/cbdd.14179
- By:
- Publication type:
- Article
Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib.
- Published in:
- Cutis, 2023, v. 111, n. 1, p. 10, doi. 10.12788/cutis.0685
- By:
- Publication type:
- Article
Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 14, p. 7474, doi. 10.3390/ijms22147474
- By:
- Publication type:
- Article
Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 18, p. 6632, doi. 10.3390/ijms21186632
- By:
- Publication type:
- Article
Recalcitrant multi-variant lichen planus successfully treated with oral baricitinib and topical ruxolitinib cream.
- Published in:
- Dermatology Online Journal, 2024, v. 30, n. 3, p. 1, doi. 10.5070/D330363864
- By:
- Publication type:
- Article
Baricitinib or imatinib in hospitalized COVID‐19 patients: Results from COVINIB, an exploratory randomized clinical trial.
- Published in:
- Journal of Medical Virology, 2023, v. 95, n. 2, p. 1, doi. 10.1002/jmv.28495
- By:
- Publication type:
- Article
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease‐2019 (COVID‐19): A systematic review and meta‐analysis.
- Published in:
- Journal of Medical Virology, 2022, v. 94, n. 4, p. 1523, doi. 10.1002/jmv.27482
- By:
- Publication type:
- Article
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 10, p. 3319, doi. 10.3390/jcm9103319
- By:
- Publication type:
- Article
Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2023, v. 42, n. 6, p. 799, doi. 10.1007/s10096-023-04599-5
- By:
- Publication type:
- Article
Baricitinib treatment of extragenital lichen sclerosus caused by COVID‐19 vaccine.
- Published in:
- Australasian Journal of Dermatology, 2023, v. 64, n. 4, p. 574, doi. 10.1111/ajd.14172
- By:
- Publication type:
- Article
Nine cases of chronic hand and foot eczema treated with baricitinib.
- Published in:
- Australasian Journal of Dermatology, 2023, v. 64, n. 3, p. 408, doi. 10.1111/ajd.14074
- By:
- Publication type:
- Article
Successful treatment of folliculitis decalvans with baricitinib: A case series.
- Published in:
- Australasian Journal of Dermatology, 2022, v. 63, n. 2, p. 279, doi. 10.1111/ajd.13786
- By:
- Publication type:
- Article
Effective treatment of oral lichen planus with the JAK inhibitor baricitinib.
- Published in:
- Australasian Journal of Dermatology, 2022, v. 63, n. 2, p. 276, doi. 10.1111/ajd.13811
- By:
- Publication type:
- Article
Repigmentation of vitiligo with oral baricitinib.
- Published in:
- Australasian Journal of Dermatology, 2020, v. 61, n. 4, p. 374, doi. 10.1111/ajd.13348
- By:
- Publication type:
- Article
Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib—Retrospective Single-Center Study.
- Published in:
- Life (2075-1729), 2023, v. 13, n. 3, p. 755, doi. 10.3390/life13030755
- By:
- Publication type:
- Article
Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1008392
- By:
- Publication type:
- Article
Case Report: Baricitinib as an Alternative in the Maintenance Therapy for Macrophage Activation Syndrome Secondary to Nodular Panniculitis.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2024, v. 17, p. 529, doi. 10.2147/CCID.S446468
- By:
- Publication type:
- Article
Excellent Repigmentation of Generalized Vitiligo with Oral Baricitinib Combined with NB-UVB Phototherapy.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 635, doi. 10.2147/CCID.S396430
- By:
- Publication type:
- Article
Tapping the potential of baricitinib to treat early-stage type 1 diabetes.
- Published in:
- 2021
- By:
- Publication type:
- Interview
Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro.
- Published in:
- Dose-Response, 2022, v. 20, n. 2, p. 1, doi. 10.1177/15593258221105370
- By:
- Publication type:
- Article
A case in which baricitinib was effective for both rheumatoid arthritis and essential thrombocythemia.
- Published in:
- Modern Rheumatology Case Reports, 2024, v. 8, n. 1, p. 1, doi. 10.1093/mrcr/rxad012
- By:
- Publication type:
- Article
A case of extrapulmonary tuberculosis after use of baricitinib.
- Published in:
- Modern Rheumatology Case Reports, 2023, v. 7, n. 2, p. 364, doi. 10.1093/mrcr/rxac098
- By:
- Publication type:
- Article
Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 9, p. 2299, doi. 10.1007/s13555-024-01247-4
- By:
- Publication type:
- Article
Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1959, doi. 10.1007/s13555-024-01208-x
- By:
- Publication type:
- Article
Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 6, p. 1561, doi. 10.1007/s13555-024-01171-7
- By:
- Publication type:
- Article
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 919, doi. 10.1007/s13555-024-01135-x
- By:
- Publication type:
- Article
Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3209, doi. 10.1007/s13555-023-01063-2
- By:
- Publication type:
- Article
Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 2951, doi. 10.1007/s13555-023-01044-5
- By:
- Publication type:
- Article